Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International (NASDAQ:DYAI) announced significant advancements on August 13, 2020, including a fully funded collaboration with a top five global pharmaceutical company for COVID-19 therapeutics. The company is also conducting animal trials for its SARS-CoV-2 vaccine candidate, with promising results. Dyadic's financial position remains strong, with approximately $11.8 million in cash and a $50 million At The Market offering program filed. The company has also expanded its R&D collaborations, reflecting its growing portfolio and potential in the biotechnology market.